Alnylam Pharmaceuticals Inc’s recently made public that its Director PYOTT DAVID E I acquired Company’s shares for reported $2.22 million on Mar 24 ’25. In the deal valued at $299.00 per share,7,440 shares were bought.
Then, Garg Pushkal bought 5,445 shares, generating $1,633,500 in total proceeds.
Before that, Garg Pushkal bought 4,321 shares. Alnylam Pharmaceuticals Inc shares valued at $1,231,485 were divested by the Officer at a price of $285.00 per share.
JP Morgan upgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to an Overweight from a a Neutral in a research note published on March 24, 2025; the price target was increased to $328 from $280. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who decreased its forecast for the stock in mid November from “a Peer perform” to “an Underperform”. Scotiabank began covering ALNY with “Sector outperform” recommendation on October 16, 2024. Goldman revised its rating on August 16, 2024. It rated ALNY as “a Buy” which previously was an “a Neutral”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock jump 2.60% to $290.70. Over the last five days, the stock has gained 14.85%. Alnylam Pharmaceuticals Inc shares have risen nearly 23.54% since the year began. Nevertheless, the stocks have risen 96.43% over the past one year. While a 52-week high of $304.39 was reached on 03/24/25, a 52-week low of $141.98 was recorded on 03/11/25. SMA at 50 days reached $257.65, while 200 days put it at $253.15.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 285.35, which if violated will result in even more drops to 279.99. On the upside, there is a resistance level at 298.48. A further resistance level may holdings at 306.25. The Relative Strength Index (RSI) on the 14-day chart is 71.41, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 24.57, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 14.55%. Stochastics %K at 81.69% indicates the stock is a selling.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2025-02-28, dropping by -0.45 million shares to a total of 2.49 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 2.94 million shares. There was a decline of -18.05%, which implies that there is a negative sentiment for the stock.
